Phase-Based Financing in Drug Development
A biotech company's biggest value jumps generally occur long before it starts generating revenue — at the moment a clinical phase result is announced.
How risk profile shifts across clinical phases
As a drug candidate moves through phase one, phase two, and phase three clinical trials, the risk of failure generally decreases at each stage; the drug's valuation therefore generally rises significantly at the end of each phase.
Early-phase investors take on much greater failure risk and generally benefit from a much lower entry valuation in return.
The structure of phase-based financing rounds
Biotech companies generally run separate financing rounds dedicated to each clinical phase; this structure lets investors put their capital at risk only up to the next concrete milestone.
This staged approach means the company does not need to raise the full cost of the entire development process at once, and it limits total capital loss if a given phase fails.
The role of milestone payments in licensing deals
Licensing agreements with large pharmaceutical companies are generally structured as an upfront payment plus additional payments tied to specific clinical and regulatory milestones; this structure splits risk between the two parties.
In a valuation analysis, the probability of each contingent payment materializing should be modeled separately and discounted to a probability-weighted present value.
How phase transition failure affects valuation
A clinical trial failing to meet its primary endpoint can trigger a sudden, sharp drop in company value; this risk should be explicitly captured in probability-based valuation models such as risk-adjusted net present value.
Companies overly dependent on a single drug candidate are far more fragile to such failures than companies with a diversified portfolio.
The role of portfolio diversification in risk management
A company carrying multiple drug candidates across different development stages can limit the impact of any single failure on total value; this diversification can translate into a lower risk premium in investors' eyes.
However, an overly broad portfolio can also spread resources thin and leave individual programs underfunded; striking the right balance is itself a signal of management quality.
Healthcare and Life SciencesIn healthcare the payback period is long and tightly bound to the regulatory framework; the financing structure must take account of both.
Learn moreFrequently asked questions
Why don't drug companies fund the entire development process in a single financing round?
Because total failure risk is very high; phase-based financing lets investors take on risk incrementally and update the valuation with new information at each stage.
Why is a phase three trial more costly than phase two?
Because it generally covers much larger patient populations, longer follow-up periods, and more clinical sites.
Are milestone payments guaranteed?
No; they are paid only if the specified clinical or regulatory target is met, so they should be valued on a probability-weighted basis.
NART Insights
Currency Risk and Financing in Export Manufacturing
For a manufacturer with high export revenue, currency risk is not just accounting — it is a strategic element shaping financing structure.
Learn moreFinancial Return Analysis of Automation Investment
The real return on an automation investment should be measured not just through labor savings, but together with quality gains and flexibility.
Learn moreSingle-Source Supply Risk and Valuation
A manufacturer sourcing a critical input from a single supplier carries a risk invisible on the financial statements but requiring a real valuation discount.
Learn moreStart a mandate discussion
Tell us about your capital requirement, your transaction idea or your structuring problem. The first assessment meeting is free of charge and strictly confidential.